Key Points
- Insider sale: CeriBell VP David Foehr sold 9,255 shares for approximately $224,434, reducing his direct ownership by 21.33% to 34,144 shares. He also sold smaller positions in August.
- Stock and earnings: CeriBell shares opened at $23.43, near their 52-week high of $25.33. The company reported quarterly revenue of $28.1 million but missed EPS expectations, posting a loss of $0.51 per share.
- Analyst outlook: Analysts maintain a consensus “Moderate Buy” rating with a $24.40 price target, although ratings range from “Strong Buy” to “Sell.” Recent price-target increases include BTIG’s $30 target and Raymond James’ $29 target.
CeriBell, Inc. (NASDAQ:CBLL - Get Free Report) CTO Raymond Woo sold 4,887 shares of the stock in a transaction on Tuesday, September 8th. The stock was sold at an average price of $24.33, for a total value of $118,900.71. Following the sale, the chief technology officer directly owned 203,118 shares in the company, valued at approximately $4,941,860.94. This trade represents a 2.35% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link.
Raymond Woo also recently made the following trade(s):
- On Friday, August 21st, Raymond Woo sold 1,979 shares of CeriBell stock. The shares were sold at an average price of $24.02, for a total transaction of $47,535.58.
CeriBell Price Performance
CeriBell stock opened at $23.43 on Friday. The company has a debt-to-equity ratio of 0.16, a quick ratio of 8.79 and a current ratio of 9.18. CeriBell, Inc. has a 52 week low of $10.85 and a 52 week high of $25.33. The stock has a market capitalization of $899.24 million, a P/E ratio of -13.31 and a beta of 0.95. The stock has a fifty day moving average of $21.03 and a 200-day moving average of $19.61.
CeriBell (NASDAQ:CBLL - Get Free Report) last released its quarterly earnings data on Monday, August 10th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.47) by ($0.04). The company had revenue of $28.10 million for the quarter, compared to analyst estimates of $27.28 million. CeriBell had a negative return on equity of 44.85% and a negative net margin of 64.73%. On average, sell-side analysts expect that CeriBell, Inc. will post -1.96 earnings per share for the current fiscal year.
Institutional Investors Weigh In On CeriBell
A number of hedge funds have recently added to or reduced their stakes in the business. BlackRock Inc. acquired a new position in shares of CeriBell during the 2nd quarter valued at $37,657,000. Vanguard Group Inc. increased its stake in CeriBell by 11.1% in the third quarter. Vanguard Group Inc. now owns 1,473,856 shares of the company's stock valued at $16,935,000 after purchasing an additional 147,013 shares in the last quarter. KCM Capital Inc raised its holdings in shares of CeriBell by 40.0% during the first quarter. KCM Capital Inc now owns 1,400,000 shares of the company's stock valued at $25,662,000 after purchasing an additional 400,000 shares during the period. Yu Fan boosted its position in shares of CeriBell by 10.7% during the 2nd quarter. Yu Fan now owns 1,353,166 shares of the company's stock worth $25,345,000 after purchasing an additional 130,964 shares in the last quarter. Finally, Bank of New York Mellon Corp grew its stake in shares of CeriBell by 1,945.9% in the 4th quarter. Bank of New York Mellon Corp now owns 1,221,927 shares of the company's stock valued at $26,797,000 after buying an additional 1,162,200 shares during the period.
Analyst Ratings Changes
Several analysts recently weighed in on the stock. Raymond James Financial reissued a "strong-buy" rating and issued a $29.00 price objective on shares of CeriBell in a research note on Thursday, September 3rd. Barclays raised CeriBell to a "neutral" rating in a research note on Tuesday, August 18th. Canaccord Genuity Group upped their target price on CeriBell from $25.00 to $26.00 and gave the company a "buy" rating in a report on Tuesday, August 11th. BTIG Research increased their target price on shares of CeriBell from $28.00 to $30.00 and gave the company a "buy" rating in a research report on Tuesday, August 18th. Finally, Weiss Ratings lowered shares of CeriBell from a "sell (d-)" rating to a "sell (e+)" rating in a research note on Friday, August 28th. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $24.40.
View Our Latest Analysis on CeriBell
About CeriBell
(
Get Free Report)
CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell's solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.
The company's product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
